Navigation Links
pORF-PLAP from InvivoGen

ProductspORF-PLAP from InvivoGen
Company InvivoGen
Item pORF-PLAP
Price $350.00
Description Plasmid expressing PLAP reporter gene.
Info InvivoGenInvivoGen
3950 Sorrento Valley Blvd, Suite A
San Diego, California 92121, USA

Cayla - InvivoGen Europe
5, rue Jean Rodier
F-31400 Toulouse, FRANCE

Customer Service:
888 457 5873
858 457 5873
+33 (0)5 62 71 69 39

Fax Number:
858 457 5843
+33 (0)5 62 71 69 30

Web Site: http://www.invivogen.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. pORF39-Hph from InvivoGen
2. pORF39-Sh ble from InvivoGen
3. pORF39-Pac from InvivoGen
4. pORF-eSEAP from InvivoGen
5. pORF39-Bsr from InvivoGen
6. pORF-LacZ from InvivoGen
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2From fruit fly wings to heart failure -- why Not(ch)? 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2Sunrise Reports Financial Results for Second Quarter 2009 53821 1Sunrise Reports Financial Results for Second Quarter 2009 53821 2Sunrise Reports Financial Results for Second Quarter 2009 53821 3Sunrise Reports Financial Results for Second Quarter 2009 53821 4Sunrise Reports Financial Results for Second Quarter 2009 53821 5Sunrise Reports Financial Results for Second Quarter 2009 53821 6Sunrise Reports Financial Results for Second Quarter 2009 53821 7Sunrise Reports Financial Results for Second Quarter 2009 53821 8Sunrise Reports Financial Results for Second Quarter 2009 53821 9Sunrise Reports Financial Results for Second Quarter 2009 53821 10Sunrise Reports Financial Results for Second Quarter 2009 53821 11Sunrise Reports Financial Results for Second Quarter 2009 53821 12Sunrise Reports Financial Results for Second Quarter 2009 53821 13Sunrise Reports Financial Results for Second Quarter 2009 53821 14Sunrise Reports Financial Results for Second Quarter 2009 53821 15Sunrise Reports Financial Results for Second Quarter 2009 53821 16Sunrise Reports Financial Results for Second Quarter 2009 53821 17Sunrise Reports Financial Results for Second Quarter 2009 53821 18Sunrise Reports Financial Results for Second Quarter 2009 53821 19Sunrise Reports Financial Results for Second Quarter 2009 53821 20Micromet Inc Reports Second Quarter 2009 Financial Results 53819 1Micromet Inc Reports Second Quarter 2009 Financial Results 53819 2Micromet Inc Reports Second Quarter 2009 Financial Results 53819 3Micromet Inc Reports Second Quarter 2009 Financial Results 53819 4Micromet Inc Reports Second Quarter 2009 Financial Results 53819 5Micromet Inc Reports Second Quarter 2009 Financial Results 53819 6Micromet Inc Reports Second Quarter 2009 Financial Results 53819 7Micromet Inc Reports Second Quarter 2009 Financial Results 53819 8Micromet Inc Reports Second Quarter 2009 Financial Results 53819 9Micromet Inc Reports Second Quarter 2009 Financial Results 53819 10Micromet Inc Reports Second Quarter 2009 Financial Results 53819 11Ben Shappley Joins Amedicas Leadership Team 53817 1Ben Shappley Joins Amedicas Leadership Team 53817 2
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6